PRIMA PFO Migraine Trial (PRIMA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00505570 |
Recruitment Status :
Terminated
First Posted : July 23, 2007
Last Update Posted : February 4, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Migraine Migraine With Aura Patent Foramen Ovale PFO | Device: AMPLATZER® PFO Occluder Device | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 107 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial) |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | February 2013 |
Actual Study Completion Date : | February 2013 |

Arm | Intervention/treatment |
---|---|
No Intervention: Medical Management | |
Experimental: PFO Closure |
Device: AMPLATZER® PFO Occluder Device
PFO device closure |
- Migraine headache frequency [ Time Frame: 12 months ]
- Responder rate; Acute migraine medication use; Quality of life evaluations; Effects of Anti-thrombotic medications; Adverse events; PFO Closure [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects who are age 18 to 65
- Subjects who have migraine headaches with aura diagnosed by a doctor
- Subjects who have not responded to or cannot take common migraine preventive medications
Exclusion Criteria:
- Subjects with a clinical history of stroke
- Subjects who cannot take aspirin and clopidogrel (Plavix)
- Subjects who are pregnant or desire to become pregnant within the next year

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00505570

Study Chair: | Prima Trial Steering Committee |
Responsible Party: | Abbott Medical Devices |
ClinicalTrials.gov Identifier: | NCT00505570 |
Other Study ID Numbers: |
AGA010E |
First Posted: | July 23, 2007 Key Record Dates |
Last Update Posted: | February 4, 2019 |
Last Verified: | February 2019 |
Migraine Migraine with aura Patent foramen ovale PFO |
Migraine Disorders Migraine with Aura Foramen Ovale, Patent Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Heart Septal Defects, Atrial Heart Septal Defects Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities |